Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody

​Sanofi and Kali Therapeutics have signed an exclusive global licence agreement for KT501, a new tri-specific antibody for B cell-mediated autoimmune diseases.

The post Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.